TAYLOR KING: Open Payments
NPI 1972258226 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,912 in 126 payments from 18 companies in 2025. Trend: 2023 $362 · 2024 $2,129 · 2025 $2,912
Food & beverage: $2,912
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $553 |
| Janssen Biotech, Inc. | 17 | $492 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $487 |
| Madrigal Pharmaceuticals | 12 | $277 |
| GENZYME CORPORATION | 12 | $211 |
| Regeneron Pharmaceuticals, Inc. | 1 | $124 |
| Lilly USA, LLC | 5 | $119 |
| Phathom Pharmaceuticals, Inc. | 7 | $117 |
| Boston Scientific Corporation | 1 | $117 |
| Ardelyx, Inc. | 6 | $114 |
Products named: TREMFYA, DUPIXENT, ENTYVIO, REZDIFFRA, RINVOQ, OMVOH, LINZESS, VOQUEZNA.
Industry payments across IN — which companies pay providers there.
